DNA Methylation Identifies Epigenetic Subtypes of Triple-Negative Breast Cancers with Distinct Clinicopathologic and Molecular Features.

[1]  Yunni-Yi Chen,et al.  Triple-Negative Apocrine Carcinomas: Toward a Unified Group With Shared Molecular Features and Clinical Behavior. , 2023, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[2]  Tanya Gupta,et al.  Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer , 2022, Breast Cancer Research and Treatment.

[3]  H. Pass,et al.  DNA methylation profiling identifies subgroups of lung adenocarcinoma with distinct immune cell composition, DNA methylation age, and clinical outcome. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  Sung-Bae Kim,et al.  Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer , 2022, New England Journal of Medicine.

[5]  J. Balko,et al.  Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes , 2021, Nature Communications.

[6]  M. Vietri,et al.  DNA methylation and breast cancer: A way forward (Review). , 2021, International journal of oncology.

[7]  A. Córdoba Iturriagagoitia,et al.  A DNA Methylation-Based Gene Signature Can Predict Triple-Negative Breast Cancer Diagnosis , 2021, Biomedicines.

[8]  Huina Zhang,et al.  HER2-Low Breast Cancers. , 2021, American journal of clinical pathology.

[9]  Kelsey Zhu,et al.  Genetic profile of primary mucinous cystadenocarcinoma of the breast—A case report , 2021, The breast journal.

[10]  Zhiqiang Zhang,et al.  Identification of a DNA Methylation-Based Prognostic Signature for Patients with Triple-Negative Breast Cancer , 2021, Medical science monitor : international medical journal of experimental and clinical research.

[11]  Ghaneya Al-Khadairi,et al.  Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects , 2021, Frontiers in Oncology.

[12]  David T. W. Jones,et al.  Sarcoma classification by DNA methylation profiling , 2021, Nature Communications.

[13]  Hiu Ting Chan,et al.  Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with Genexus™ integrated sequencer , 2021, Translational lung cancer research.

[14]  M. Ellis,et al.  Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group , 2020, Journal of the National Cancer Institute.

[15]  Xuning Wang,et al.  Genome-Wide Analysis of Methylation-Driven Genes and Identification of an Eight-Gene Panel for Prognosis Prediction in Breast Cancer , 2020, Frontiers in Genetics.

[16]  L. Cope,et al.  DNA methylation markers predict recurrence-free interval in triple-negative breast cancer , 2020, npj Breast Cancer.

[17]  A. Córdoba,et al.  ADAM12 is A Potential Therapeutic Target Regulated by Hypomethylation in Triple-Negative Breast Cancer , 2020, International journal of molecular sciences.

[18]  C. Perou,et al.  Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Xiaofeng Dai,et al.  DNA methylation profiles capturing breast cancer heterogeneity , 2019, BMC Genomics.

[20]  S. Sinha,et al.  Coupled Genome-Wide DNA Methylation and Transcription Analysis Identified Rich Biomarkers and Drug Targets in Triple-Negative Breast Cancer , 2019, Cancers.

[21]  M. Salomon,et al.  Clinicopathological Features of Triple-Negative Breast Cancer Epigenetic Subtypes , 2019, Annals of Surgical Oncology.

[22]  N. Turner,et al.  Targeting the PI3-kinase pathway in triple negative breast cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  M. Ladanyi,et al.  DNA methylation-based classification of sinonasal undifferentiated carcinoma , 2019, Modern Pathology.

[24]  E. King,et al.  Pan-cancer deconvolution of tumour composition using DNA methylation , 2018, Nature Communications.

[25]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Reis-Filho,et al.  Triple-negative breast cancers — a panoply of cancer types , 2018, Nature Reviews Clinical Oncology.

[27]  David T. W. Jones,et al.  DNA methylation-based classification of central nervous system tumours , 2018, Nature.

[28]  C. Sotiriou,et al.  Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  I. Ellis,et al.  The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions. , 2017, The American journal of pathology.

[30]  M. Robson,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.

[31]  M. Ladanyi,et al.  DNA Methylation-Based Classifier for Accurate Molecular Diagnosis of Bone Sarcomas. , 2017, JCO precision oncology.

[32]  J. Forbes,et al.  DNA methylation profile of triple negative breast cancer-specific genes comparing lymph node positive patients to lymph node negative patients , 2016, Scientific Reports.

[33]  Roland Eils,et al.  Complex heatmaps reveal patterns and correlations in multidimensional genomic data , 2016, Bioinform..

[34]  Obi L. Griffith,et al.  GenVisR: Genomic Visualizations in R , 2016, bioRxiv.

[35]  Rodney J Scott,et al.  Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value , 2015, Nature Communications.

[36]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[38]  Gordon B Mills,et al.  Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer , 2014, Clinical Cancer Research.

[39]  Rafael A. Irizarry,et al.  Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays , 2014, Bioinform..

[40]  W. Jones,et al.  Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation. , 2013, Experimental and molecular pathology.

[41]  Stefan Michiels,et al.  Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  C. Perou,et al.  Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. , 2013, The oncologist.

[43]  D. Marzese,et al.  Methylation profile of triple-negative breast carcinomas , 2012, Oncogenesis.

[44]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[45]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[46]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[47]  Shu Ichihara,et al.  Breast cancer prognostic classification in the molecular era: the role of histological grade , 2010, Breast Cancer Research.

[48]  R. Gelber,et al.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[50]  M. Snuderl,et al.  Whole Genome DNA Methylation Analysis of Human Glioblastoma Using Illumina BeadArrays. , 2018, Methods in molecular biology.

[51]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..